CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
+36.05%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$622M
AUM Growth
+$622M
(+31%)
Cap. Flow
+$76.5M
Cap. Flow
% of AUM
12.3%
Top 10 Holdings %
Top 10 Hldgs %
69.69%
Holding
34
New
10
Increased
3
Reduced
3
Closed
4
Top Buys
| 1 |
Akero Therapeutics
AKRO
|
$25.3M |
| 2 |
Viridian Therapeutics
VRDN
|
$21.7M |
| 3 |
THRD
Third Harmonic Bio
THRD
|
$19.3M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$17.7M |
| 5 |
Acumen Pharmaceuticals
ABOS
|
$11M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$23.2M |
| 2 |
Kura Oncology
KURA
|
$12.7M |
| 3 |
VistaGen Therapeutics
VTGN
|
$11.5M |
| 4 |
Cogent Biosciences
COGT
|
$9.32M |
| 5 |
Tenaya Therapeutics
TNYA
|
$2.01M |
Sector Composition
| 1 | Healthcare | 99.6% |
| 2 | Financials | 0.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cogent Biosciences
COGT
$1.69B
| $64.5M | 10.36% | 4,319,940 -624,768 | -13% | -$9.32M |
|
2
Xenon Pharmaceuticals
XENE
$2.98B
| $57.6M | 9.26% | 1,594,932 | – | – |
|
|
3
Viridian Therapeutics
VRDN
$1.5B
| $55.3M | 8.89% | 2,696,340 +1,057,731 | +65% | +$21.7M |
|
|
BLU
4
DELISTED
BELLUS Health Inc.
BLU
| $54.2M | 8.71% | 5,128,557 +648,773 | +14% | +$6.85M |
|
5
Merus
MRUS
$4.98B
| $52.4M | 8.43% | 2,615,762 | – | – |
|
6
Cytokinetics
CYTK
$4.23B
| $43.3M | 6.96% | 893,646 | – | – |
|
7
Aclaris Therapeutics
ACRS
$209M
| $37.9M | 6.1% | 2,410,622 | – | – |
|
|
8
Akero Therapeutics
AKRO
$3.74B
| $25.3M | 4.07% | +743,472 | New | +$25.3M |
|
|
STSA
9
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $22.3M | 3.58% | 3,711,286 | – | – |
|
|
TCDA
10
DELISTED
Tricida, Inc. Common Stock
TCDA
| $20.7M | 3.33% | 1,975,403 -53,050 | -3% | -$556K |
|
|
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
| $20.1M | 3.23% | 5,738,500 | – | – |
|
|
THRD
12
DELISTED
Third Harmonic Bio
THRD
| $19.3M | 3.11% | +1,018,569 | New | +$19.3M |
|
|
13
Syndax Pharmaceuticals
SNDX
$1.41B
| $17.7M | 2.85% | +738,110 | New | +$17.7M |
|
14
Celldex Therapeutics
CLDX
$1.47B
| $15.1M | 2.44% | 538,812 | – | – |
|
15
Day One Biopharmaceuticals
DAWN
$769M
| $14.8M | 2.38% | 739,661 | – | – |
|
16
Arrowhead Research
ARWR
$3.05B
| $13.4M | 2.15% | 404,078 +91,545 | +29% | +$3.03M |
|
|
17
Kura Oncology
KURA
$686M
| $12.3M | 1.98% | 899,407 -927,084 | -51% | -$12.7M |
|
|
18
Acumen Pharmaceuticals
ABOS
$82.4M
| $11M | 1.77% | +1,100,000 | New | +$11M |
|
19
Karyopharm Therapeutics
KPTI
$61.7M
| $10.6M | 1.7% | 1,935,609 | – | – |
|
|
ALLK
20
DELISTED
Allakos
ALLK
| $10.1M | 1.62% | +1,643,500 | New | +$10.1M |
|
|
ALPN
21
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $9.54M | 1.53% | +1,325,000 | New | +$9.54M |
|
22
Celcuity
CELC
$2.17B
| $9.24M | 1.49% | 920,464 | – | – |
|
23
Enanta Pharmaceuticals
ENTA
$180M
| $5.37M | 0.86% | +103,494 | New | +$5.37M |
|
24
KalVista Pharmaceuticals
KALV
$678M
| $4.54M | 0.73% | 312,553 | – | – |
|
25
Rezolute
RZLT
$619M
| $3.32M | 0.53% | 1,210,000 | – | – |
|